ARTICLE
1 May 2025

Canada's Drug Agency Releases 2025 Watch List Highlighting AI Technologies In Health Care

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada.
Canada Food, Drugs, Healthcare, Life Sciences

On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada. The 2025 Watch List highlights the top AI technologies and related issues poised to impact health care systems in Canada.

Top five AI technologies:

  • AI for notetaking
  • AI in clinical training
  • AI for disease diagnosis
  • AI for disease treatment
  • AI for remote monitoring

Top five issues:

  • Privacy & data security
  • Liability & accountability
  • Data availability, quality & bias
  • Data sovereignty & governance
  • Environmental costs

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More